When The Mighty Fall, Smaller Vaccine Players Seize The COVID Day
Agile Decisions Make The Difference
Executive Summary
While global vaccine heavyweights such as Merck & Co, Sanofi and GSK have somewhat lagged in the development of vaccines for COVID-19, smaller players have stepped up. This is especially true for highly segmented markets such as China, where agility has been important.
You may also be interested in...
Seizing The Day: How Coronavirus Breaks Then Makes Vaccine Makers In China
Amid fears of a second wave of coronavirus infections and the increasing dominance of state-owned enterprises, private vaccine makers in China are struggling to make the best of the outbreak, BravoVax CEO Ke Wu tells Scrip in an exclusive interview.
Race On: China Starts Coronavirus Vaccine Trial, Vows Fast Development
Leveraging on its Ebola vaccine success, Tianjin-based CanSino is testing its vaccine on humans in Wuhan and hopes to get China’s first COVID-19 vaccine on the market soon.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.